产前硫酸镁对早产儿神经保护作用的个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入5项随机试验、5493名孕妇和6131名婴儿,评估产前硫酸镁与不用镁对早产儿死亡或脑瘫等结局的影响。总体复合结局未见明确效应(RR 0.94,95%CI 0.85–1.05),但在以胎儿神经保护为治疗意图的4项试验中,死亡或脑瘫风险显著降低(RR 0.86,95%CI 0.75–0.99)。作者认为产前硫酸镁可预防脑瘫并降低死亡或脑瘫的复合风险。
要点
- 在以胎儿神经保护为意图的试验中,硫酸镁降低死亡或脑瘫风险(RR 0.86,95%CI 0.75–0.99)。
- 存活儿脑瘫风险在总体分析(RR 0.68,95%CI 0.54–0.87)与神经保护意图分析(RR 0.68,95%CI 0.53–0.87)中均降低。
- 总体分析中死亡或脑瘫复合结局未见明确效应(RR 0.94,95%CI 0.85–1.05)。
核心结论
- 产前硫酸镁用于胎儿神经保护可预防脑瘫,并降低胎儿或婴儿死亡与脑瘫的复合风险。
- 无论早产原因如何均可见获益,且在不同早产孕周和不同治疗方案间效应相似。
- 作者认为全球广泛采用这一相对廉价、易于给药的治疗将带来重要全球健康获益。
研究设计与样本
- 个体参与者数据荟萃分析,纳入5项随机试验,共5493名孕妇和6131名婴儿。
- 纳入标准为将早产风险(<37周妊娠)妇女随机分配至硫酸镁或对照治疗并报告婴儿神经结局的试验。
- 检索采用Cochrane妊娠与分娩检索策略,检索词为[产前或 prenatal]与[镁]与[早产或神经保护或脑瘫],最后检索日期为2017年2月28日。
- 偏倚风险采用Cochrane协作网标准评估,每个预设结局采用一阶段法分析个体参与者数据。
主要发现
- 总体分析中,硫酸镁治疗与不用治疗相比,婴儿死亡或脑瘫复合结局未见明确效应(RR 0.94,95%CI 0.85–1.05,6131名婴儿,5项试验,试验间治疗效应异质性p=0.07)。
- 在仅限4项以胎儿神经保护为治疗意图试验的预设敏感性分析中,硫酸镁治疗较不用治疗显著降低死亡或脑瘫风险(RR 0.86,95%CI 0.75–0.99,4448名婴儿,4项试验),无异质性(p=0.28)。
- 总体死亡未见效应(RR 1.03,95%CI 0.91–1.17,6131名婴儿,5项试验);神经保护意图分析中死亡亦未见效应(RR 0.95,95%CI 0.80–1.13,4448名婴儿,4项试验)。
- 存活儿脑瘫在总体分析中呈强保护效应(RR 0.68,95%CI 0.54–0.87,4601名婴儿,5项试验),神经保护意图分析中同样为RR 0.68(95%CI 0.53–0.87,3988名婴儿,4项试验)。
- 治疗效应在早产原因、给药孕周、总剂量及是否使用维持治疗间差异很小;其他次要结局均未见统计学显著差异。
关键数值与推荐
- 总体分析死亡或脑瘫:RR 0.94,95%CI 0.85–1.05,6131名婴儿,5项试验。
- 神经保护意图分析死亡或脑瘫:RR 0.86,95%CI 0.75–0.99,4448名婴儿,4项试验,获益需治疗人数(NNT)为41名妇女/婴儿预防1名婴儿死亡或发生脑瘫。
- 总体分析存活儿脑瘫:RR 0.68,95%CI 0.54–0.87,4601名婴儿,5项试验,NNT为46。
- 神经保护意图分析存活儿脑瘫:RR 0.68,95%CI 0.53–0.87,3988名婴儿,4项试验,NNT为42。
- 严重孕产妇结局(潜在与硫酸镁治疗相关):提供数据的2项试验未记录到事件。
临床怎么用
- 作者认为,产前硫酸镁用于胎儿神经保护可预防脑瘫并降低死亡或脑瘫复合风险,全球广泛采用可带来重要健康获益。
- 作者指出获益与早产原因无关,在不同早产孕周和不同治疗方案间效应相似。
局限性
- 并非所有试验都能提供计划分析所需的数据,加之部分重要临床事件发生率低,发现差异的检验效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Babies born preterm are at an increased risk of dying in the first weeks of life, and those who survive have a higher rate of cerebral palsy (CP) compared with babies born at term. The aim of this individual participant data (IPD) meta-analysis (MA) was to assess the effects of antenatal magnesium sulphate, compared with no magnesium treatment, given to women at risk of preterm birth on important maternal and fetal outcomes, including survival free of CP, and whether effects differed by participant or treatment characteristics such as the reason the woman was at risk of preterm birth, why treatment was given, the gestational age at which magnesium sulphate treatment was received, or the dose and timing of the administration of magnesium sulphate. METHODS AND FINDINGS: Trials in which women considered at risk of preterm birth (<37 weeks' gestation) were randomised to magnesium sulphate or control treatment and where neurologic outcomes for the baby were reported were eligible for inclusion. The primary outcomes were infant death or CP and severe maternal outcome potentially related to treatment. Studies were identified based on the Cochrane Pregnancy and Childbirth search strategy using the terms [antenatal or prenatal] and [magnesium] and [preterm or premature or neuroprotection or 'cerebral palsy']. The date of the last search was 28 February 2017. IPD were sought from investigators with eligible trials. Risk of bias was assessed using criteria from the Cochrane Collaboration. For each prespecified outcome, IPD were analysed using a 1-stage approach. All 5 trials identified were included, with 5,493 women and 6,131 babies. Overall, there was no clear effect of magnesium sulphate treatment compared with no treatment on the primary infant composite outcome of death or CP (relative risk [RR] 0.94, 95% confidence interval (CI) 0.85 to 1.05, 6,131 babies, 5 trials, p = 0.07 for heterogeneity of treatment effect across trials). In the prespecified sensitivity analysis restricted to data from the 4 trials in which the intent of treatment was fetal neuroprotection, there was a significant reduction in the risk of death or CP with magnesium sulphate treatment compared with no treatment (RR 0.86, 95% CI 0.75 to 0.99, 4,448 babies, 4 trials), with no significant heterogeneity (p = 0.28). The number needed to treat (NNT) to benefit was 41 women/babies to prevent 1 baby from either dying or having CP. For the primary outcome of severe maternal outcome potentially related to magnesium sulphate treatment, no events were recorded from the 2 trials providing data. When the individual components of the composite infant outcome were assessed, no effect was seen for death overall (RR 1.03, 95% CI 0.91 to 1.17, 6,131 babies, 5 trials) or in the analysis of death using only data from trials with the intent of fetal neuroprotection (RR 0.95, 95% CI 0.80 to 1.13, 4,448 babies, 4 trials). For cerebral palsy in survivors, magnesium sulphate treatment had a strong protective effect in both the overall analysis (RR 0.68, 95% CI 0.54 to 0.87, 4,601 babies, 5 trials, NNT to benefit 46) and the neuroprotective intent analysis (RR 0.68, 95% CI 0.53 to 0.87, 3,988 babies, 4 trials, NNT to benefit 42). No statistically significant differences were seen for any of the other secondary outcomes. The treatment effect varied little by the reason the woman was at risk of preterm birth, the gestational age at which magnesium sulphate treatment was given, the total dose received, or whether maintenance therapy was used. A limitation of the study was that not all trials could provide the data required for the planned analyses so that combined with low event rates for some important clinical events, the power to find a difference was limited. CONCLUSIONS: Antenatal magnesium sulphate given prior to preterm birth for fetal neuroprotection prevents CP and reduces the combined risk of fetal/infant death or CP. Benefit is seen regardless of the reason for preterm birth, with similar effects across a range of preterm gestational ages and different treatment regimens. Widespread adoption worldwide of this relatively inexpensive, easy-to-administer treatment would lead to important global health benefits for infants born preterm.
引用
- Crowther CA, Middleton PF, Voysey M, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med. 2017. PMID: 28976987. doi:10.1371/journal.pmed.1002398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。